Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pamrevlumab + nintedanib
- Development stage
- Unknown
- Lead developer
- FibroGen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Pamrevlumab + nintedanib is a combination therapy under investigation for the treatment of idiopathic pulmonary fibrosis (IPF). **Pamrevlumab** is a fully human monoclonal antibody targeting and inhibiting connective tissue growth factor (CTGF), a key mediator in the development and progression of fibrosis. **Nintedanib** is a small molecule, triple angiokinase inhibitor that targets receptor tyrosine kinases including platelet-derived growth factor receptor (PDGFR) α/β, fibroblast growth factor receptor (FGFR) 1/2/3, and vascular endothelial growth factor receptor (VEGFR) 1/2/3, inhibiting fibroblast proliferation, migration, and transformation. Combination therapy aims to address multiple pathways implicated in fibrotic lung disease. **Pamrevlumab** is developed by FibroGen; **nintedanib** was developed by Boehringer Ingelheim and marketed as Ofev[1][3][4][5].
- Other names
- pamrevlumabnintedanib
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)LYN (LYN proto-oncogene, Src family tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)CTGF (Connective tissue growth factor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)FLT3 (Fms related receptor tyrosine kinase 3)LCK (Proto-oncogene tyrosine-protein kinase Lck)
Beyond the preview
Go deeper on pamrevlumab + nintedanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pamrevlumab + nintedanib.